Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y
Thorac Cancer. 2022; 13(19):2776-2785.
PMID: 36062426
PMC: 9527159.
DOI: 10.1111/1759-7714.14621.
Shiono A, Imai H, Wasamoto S, Tsuda T, Nagai Y, Minemura H
Cancer Med. 2022; 12(1):73-83.
PMID: 35699088
PMC: 9844637.
DOI: 10.1002/cam4.4938.
Wu X, Wang L, Feng F, Tian S
J Int Med Res. 2019; 48(3):300060519893837.
PMID: 31854219
PMC: 7607763.
DOI: 10.1177/0300060519893837.
Deng L, Zhou Z, Xiao Z, Chen D, Feng Q, Liang J
Thorac Cancer. 2019; 10(4):799-806.
PMID: 30779334
PMC: 6449270.
DOI: 10.1111/1759-7714.13001.
Imai H, Yamada Y, Minemura H, Sugiyama T, Kotake M, Kaira K
Thorac Cancer. 2018; 9(12):1699-1706.
PMID: 30281216
PMC: 6275829.
DOI: 10.1111/1759-7714.12884.
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Xu F, Ren X, Chen Y, Li Q, Li R, Chen Y
BMC Cancer. 2018; 18(1):808.
PMID: 30097029
PMC: 6086076.
DOI: 10.1186/s12885-018-4715-9.
Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Imai H, Mori K, Watase N, Kazama T, Fujimoto S, Kaira K
Thorac Cancer. 2016; 7(6):655-662.
PMID: 27755823
PMC: 5093173.
DOI: 10.1111/1759-7714.12381.
Clinical Significance of the Relationship between Progression-Free Survival or Postprogression Survival and Overall Survival in Patients with Extensive Disease-Small-Cell Lung Cancer Treated with Carboplatin plus Etoposide.
Imai H, Mori K, Watase N, Fujimoto S, Kaira K, Yamada M
Can Respir J. 2016; 2016:5405810.
PMID: 27445549
PMC: 4942672.
DOI: 10.1155/2016/5405810.
Survival analysis in second-line and third-line chemotherapy with irinotecan followed by topotecan or topotecan followed by irinotecan for extensive-stage small-cell lung cancer patients: a single-center retrospective study.
Aktas G, Kus T, Kalender M, Sevinc A, Camci C, Kul S
Onco Targets Ther. 2016; 9:1921-6.
PMID: 27099522
PMC: 4824370.
DOI: 10.2147/OTT.S101390.
Correlation between Semi-Quantitative (18)F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer.
Park S, Lee E, Rhee S, Cho J, Choi S, Lee S
Nucl Med Mol Imaging. 2016; 50(1):24-30.
PMID: 26941856
PMC: 4762859.
DOI: 10.1007/s13139-015-0363-z.
Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer.
Shi P, Meng X, Ni M, Sun X, Xing L, Yu J
Oncol Lett. 2016; 10(5):3123-3128.
PMID: 26722299
PMC: 4665208.
DOI: 10.3892/ol.2015.3673.
Increased Expression of Eps15 Homology Domain 1 is Associated with Poor Prognosis in Resected Small Cell Lung Cancer.
Meng Q, Sun W, Li M, Zhao Y, Chen X, Sun L
J Cancer. 2015; 6(10):990-5.
PMID: 26366212
PMC: 4565848.
DOI: 10.7150/jca.11650.
[Effects of Local Radiation Combined with Chemotherapy in the treatment of
Patients with Extensive-stage Small Cell Lung Cancer].
Wu D, Fang J, Nie J, Dai L, Chen X, Zhang J
Zhongguo Fei Ai Za Zhi. 2015; 18(5):272-9.
PMID: 25975297
PMC: 6015215.
DOI: 10.3779/j.issn.1009-3419.2015.05.04.
Small cell lung cancer: where do we go from here?.
Byers L, Rudin C
Cancer. 2014; 121(5):664-72.
PMID: 25336398
PMC: 5497465.
DOI: 10.1002/cncr.29098.
[A randomized controlled study of chemotherapy: etoposide combined with oxaliplatin or cisplatin regimens in the treatment of extensive-stage small cell lung cancer in elderly patients].
Pu D, Hou M, Li Z, Zeng X
Zhongguo Fei Ai Za Zhi. 2013; 16(1):20-4.
PMID: 23327869
PMC: 6000454.
DOI: 10.3779/j.issn.1009-3419.2013.01.04.
Small cell lung cancer.
Kalemkerian G, Akerley W, Bogner P, Borghaei H, Chow L, Downey R
J Natl Compr Canc Netw. 2013; 11(1):78-98.
PMID: 23307984
PMC: 3715060.
DOI: 10.6004/jnccn.2013.0011.
[Immediate versus delayed topotecan after first-line therapy in small cell lung cancer].
Jiang W, Zhang Y, Zhao H, Xu G, Lin L, Zhao Y
Zhongguo Fei Ai Za Zhi. 2010; 13(3):211-5.
PMID: 20673518
PMC: 6000537.
DOI: 10.3779/j.issn.1009-3419.2010.03.05.
Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer.
Kim Y, Park S, Kyung S, Sym S, Lee S, Park J
Med Oncol. 2010; 28(1):342-50.
PMID: 20198458
DOI: 10.1007/s12032-010-9453-z.
